|
|
| (49 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| | __NOTOC__ | | __NOTOC__ |
| | *'''[[Further reading]]''' | | *'''[[Further reading]]''' |
| − | {{tp|p=32251543|t=2020. The COVID-19 (Coronavirus) pandemic: reflections on the roles of librarians and information professionals |pdf=|usr=}}
| |
| − | {{tp|p=32379021|t=2020. Rapid Publication, Knowledge Sharing, and Our Responsibility During the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32358556|t=2020. Coronavirus in context: Scite ai tracks positive and negative citations for COVID-19 literature |pdf=|usr=}}
| |
| − | {{tp|p=32157233|t=2020. Keep up with the latest coronavirus research |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| | *'''[[Unproven ideas]]''' | | *'''[[Unproven ideas]]''' |
| − | *[https://www.metro.news/lockdown-law-bans-sex-if-youre-living-apart/2031854/ Kein Geschlechtsverkehr außerhalb der Ehe...]
| |
| | | | |
| | *'''[[Reviews on covid19 disease]]''' | | *'''[[Reviews on covid19 disease]]''' |
| − | {{tp|p=32170865|t=ä. Coronavirus disease 2019: What we know?|pdf=|usr=}}
| |
| − | {{tp|p=32096567|t=ä. Understanding of COVID?19 based on current evidence |pdf=|usr=}}
| |
| − | {{tp|p=32249943|t=2020. A comparative-descriptive analysis of clinical characteristics in 2019-coronavirus-infected children and adults |pdf=|usr=}}
| |
| − | {{tp|p=32320004|t=2020. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review |pdf=|usr=}}
| |
| − | {{tp|p=32273605|t=2020. Clinical and epidemiological characteristics of children with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32367025|t=2020. Profile of a killer: the complex biology powering the coronavirus pandemic |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| | *'''[[Clinical guidelines and advice]]''' | | *'''[[Clinical guidelines and advice]]''' |
| − | {{tp|p=32359076|t=2020. COVID-19: Use of the Clinical Frailty Scale for Critical Care Decisions |pdf=|usr=}}
| |
| − | {{tp|p=32215647|t=2020. Management of Critically Ill Adults With COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32159735|t=2020. Care for Critically Ill Patients With COVID-19 |pdf=|usr=}}
| |
| | | | |
| | | | |
| − |
| |
| − | {{tp|p=32369222|t=2020. The management of coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
| |
| | | | |
| | *'''[[Respiration mgmt]]''' | | *'''[[Respiration mgmt]]''' |
| − | {{tp|p=32249028|t=2020. The "helmet bundle" in COVID-19 patients undergoing non invasive ventilation |pdf=|usr=}}
| |
| − | {{tp|p=32268933|t=2020. Home PAP devices in COVID-19 infected patients |pdf=|usr=}}
| |
| − | {{tp|p=32074258|t=2020. Preparing for the Most Critically Ill Patients With COVID-19: The Potential Role of Extracorporeal Membrane Oxygenation |pdf=|usr=}}
| |
| − | {{tp|p=32329799|t=2020. Management of COVID-19 Respiratory Distress |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| | | | |
| | *'''[[Diagnosis (Laboratory)]]''' | | *'''[[Diagnosis (Laboratory)]]''' |
| − | {{ttp|p=32374370|t=2020. Interpreting Diagnostic Tests for SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32367861|t=2020. Bronchoalveolar specimen can help detect COVID-19 in suspicious case with negative PCR for nasopharyngeal specimen test |pdf=|usr=}}
| |
| − | {{tp|p=32301958|t=2020. The Promise and Peril of Antibody Testing for COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32236503|t=2020. Testing Individuals for Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32334422|t=2020. Smartphone-based multiplex 30-minute nucleic acid test of live virus from nasal swab extract |pdf=|usr=}}
| |
| − | {{tp|p=32247384|t=2020. Developing antibody tests for SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32171389|t=2020. SARS-CoV-2 RNA more readily detected in induced sputum than in throat swabs of convalescent COVID-19 patients |pdf=|usr=}}
| |
| − | {{ttp|p=32300245|t=2020. CRISPR-Cas12-based detection of SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32350462|t=2020. Antibody responses to SARS-CoV-2 in patients with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32273607|t=2020. Virological assessment of SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32235945|t=2020. Virological assessment of hospitalized patients with COVID-2019 |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| | *'''[[Diagnosis (Lung CT, Sonography)]]''' | | *'''[[Diagnosis (Lung CT, Sonography)]]''' |
| − | {{tp|p=32280076|t=2020. Clinical and computed tomographic (CT) images characteristics in the patients with COVID-19 infection: What should radiologists need to know?|pdf=|usr=}}
| |
| − | {{tp|p=32376589|t=2020. COVID-19 CT |pdf=|usr=}}
| |
| − | {{tp|p=32376573|t=2020. COVID-19 MS-CT |pdf=|usr=}}
| |
| − | {{tp|p=32376543|t=2020. CT dandelion clock sign |pdf=|usr=}}
| |
| − | *'''[https://pubs.rsna.org/doi/10.1148/ryct.2020200210 06/01/20 COVID-19: A Multimodality Review of Radiologic Techniques, Clinical Utility, and Imaging Features btu @stevenha]'''
| |
| − |
| |
| | | | |
| | *'''[[Diagnosis (other modalities)]]''' | | *'''[[Diagnosis (other modalities)]]''' |
| | | | |
| | | | |
| − | ----
| |
| | | | |
| | | | |
| | *'''[[Structure of covid19]]''' | | *'''[[Structure of covid19]]''' |
| − | {{tp|p=32238585|t=2020. Isolation and Full-Length Genome Characterization of SARS-CoV-2 from COVID-19 Cases in Northern Italy |pdf=|usr=}}
| + | |
| − | {{tp|p=32238584|t=2020. Computational inference of selection underlying the evolution of the novel coronavirus, SARS-CoV-2 |pdf=|usr=}}
| + | |
| − | {{tp|p=32365353|t=2020. Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform |pdf=|usr=}}
| + | |
| | | | |
| | *'''[[Target binding and uptake]]''' | | *'''[[Target binding and uptake]]''' |
| − | {{tp|p=32225176|t=2020. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor |pdf=|usr=}}
| |
| − | {{tp|p=32225175|t=2020. Structural basis of receptor recognition by SARS-CoV-2 |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| | *'''[[Cytopathic effects]]''' | | *'''[[Cytopathic effects]]''' |
| − |
| |
| | *'''[[Secretion and shedding]]''' | | *'''[[Secretion and shedding]]''' |
| | | | |
| Zeile 89: |
Zeile 34: |
| | | | |
| | *'''[[Immunology]]''' | | *'''[[Immunology]]''' |
| − | {{tp|p=32376901|t=ä. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages |pdf=|usr=}}
| |
| | | | |
| | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' | | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' |
| − | {{tp|p=32343429|t=2020. Elevated Interleukin-6 and Severe COVID-19: A Meta-Analysis |pdf=|usr=}}
| |
| − | {{tp|p=32192578|t=2020. COVID-19: consider cytokine storm syndromes and immunosuppression |pdf=|usr=}}
| |
| | | | |
| − | ----
| + | |
| | + | |
| | *'''[[Pathobiology]]''' | | *'''[[Pathobiology]]''' |
| − | {{tp|p=32369204|t=2020. Hepatic involvement in COVID-19 patients: Pathology, pathogenesis, and clinical implications |pdf=|usr=}}
| |
| − | {{tp|p=32294295|t=2020. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19 |pdf=|usr=}}
| |
| − | {{ttp|p=32376101|t=ä. Association Between Hypoxemia and Mortality in Patients With COVID-19 |pdf=|usr=}}
| |
| − | {{ttp|p=32272081|t=2020. Understanding pathways to death in patients with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32327758|t=2020. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| | *'''[[Disease Models]]''' | | *'''[[Disease Models]]''' |
| − | {{tp|p=32380511|t=2020. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Similar diseases and pathomechanisms]]''' | | *'''[[Similar diseases and pathomechanisms]]''' |
| − | {{tp|p=32319148|t=2020. COVID-19: searching for clues among other respiratory viruses |pdf=|usr=}}
| |
| − | {{tp|p=32237148|t=2020. Differences between COVID-19 and suspected then confirmed SARS-CoV-2-negative pneumonia: a retrospective study from a single center |pdf=|usr=}}
| |
| − | {{tp|p=32265517|t=2020. SARS-CoV-2 detection in patients with influenza-like illness |pdf=|usr=}}
| |
| | | | |
| − | ----
| |
| | | | |
| | | | |
| Zeile 121: |
Zeile 53: |
| | | | |
| | *'''[[Systemic disease, any manifestations]]''' | | *'''[[Systemic disease, any manifestations]]''' |
| | + | |
| | *'''[[Co-Infection]]''' | | *'''[[Co-Infection]]''' |
| − | {{tp|p=32339350|t=2020. COVID-19 associated pulmonary aspergillosis |pdf=|usr=}}
| |
| | | | |
| − |
| |
| − | *'''[[ARDS]]'''
| |
| | | | |
| | *'''[[Pulmonary embolism, coagulation]]''' | | *'''[[Pulmonary embolism, coagulation]]''' |
| − | {{tp|p=32359410|t=ä. Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT |pdf=|usr=}}
| + | |
| − | {{tp|p=32369280|t=ä. Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32374956|t=2020. Acute Cor Pulmonale in Critically Ill Patients with Covid-19 |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| Zeile 136: |
Zeile 64: |
| | | | |
| | *'''[[Hematology]]''' | | *'''[[Hematology]]''' |
| − | {{tp|p=32344467|t=2020. What do monitoring platelet counts in COVID-19 teach us?|pdf=|usr=}}
| |
| − | {{tp|p=32379934|t=2020. Response to What does monitoring platelet counts in COVID-19 teach us? |pdf=|usr=}}
| |
| − | {{ttp|p=32302435|t=2020. Thrombocytopenia and its association with mortality in patients with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32278338|t=2020. Exploring possible mechanisms for COVID-19 induced thrombocytopenia: Unanswered questions |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| | *'''[[Heart]]''' | | *'''[[Heart]]''' |
| − | {{tp|p=32267000|t=2020. Patterns of heart Injury in COVID - 19 and relation to outcome |pdf=|usr=}}
| |
| − | {{tp|p=32219357|t=2020. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32219363|t=2020. Potential Effects of Coronaviruses on the Cardiovascular System: A Review |pdf=|usr=}}
| |
| − | {{tp|p=32219362|t=2020. Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality |pdf=|usr=}}
| |
| − | {{tp|p=32356626|t=ä. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| | | | |
| | *'''[[Neurology, ophthalmology, orl]]''' | | *'''[[Neurology, ophthalmology, orl]]''' |
| − | {{tp|p=32237238|t=ä. Anosmia and Ageusia: Common Findings in COVID?19 Patients |pdf=|usr=}}
| |
| − | {{tp|p=32275291|t=2020. The Spectrum of Neurologic Disease in the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic Infection: Neurologists Move to the Frontlines |pdf=|usr=}}
| |
| − | {{tp|p=32267483|t=2020. Sudden and Complete Olfactory Loss Function as a Possible Symptom of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32343504|t=ä. Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young |pdf=|usr=}}
| |
| − | {{tp|p=32376583|t=2020. COVID-19 stroke case report |pdf=|usr=}}
| |
| − | {{tp|p=32291797|t=2020. SARS-CoV-2: At the Crossroad Between Aging and Neurodegeneration |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| | | | |
| | *'''[[Dermatology]]''' | | *'''[[Dermatology]]''' |
| − | {{tp|p=32352487|t=2020. Petechial Skin Rash Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection |pdf=|usr=}}
| |
| − | {{tp|p=32352486|t=2020. Digitate Papulosquamous Eruption Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection |pdf=|usr=}}
| |
| − | {{tp|p=32352485|t=2020. How Dermatologists Can Learn and Contribute at the Leading Edge of the COVID-19 Global Pandemic |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| | | | |
| | *'''[[Gastroenterology, hepatology]]''' | | *'''[[Gastroenterology, hepatology]]''' |
| − | {{tp|p=32369204|t=2020. Hepatic involvement in COVID-19 patients: Pathology, pathogenesis, and clinical implications |pdf=|usr=}}
| |
| − | {{tp|p=32343413|t=2020. Letter to the Editor: Lipemic serum in patients with COVID-19 undergoing treatment |pdf=|usr=}}
| |
| − | {{tp|p=32314799|t=2020. Letter to the Editor: Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab |pdf=|usr=}}
| |
| − | {{tp|p=32170806|t=ä. Liver injury during highly pathogenic human coronavirus infections |pdf=|usr=}}
| |
| − | {{tp|p=32239591|t=ä. Clinical characteristics of non?ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study |pdf=|usr=}}
| |
| − | {{tp|p=32369658|t=2020. Acute on chronic liver failure from novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |pdf=|usr=}}
| |
| − | {{tp|p=32359220|t=2020. Liver injury in COVID-19: Diagnosis and associated factors |pdf=|usr=}}
| |
| − | {{tp|p=32352224|t=2020. SARS-CoV-2 virus and liver expression of host receptors: Putative mechanisms of liver involvement in COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32304343|t=2020. Bilirubin levels in patients with mild and severe Covid-19: A pooled analysis |pdf=|usr=}}
| |
| − | {{tp|p=32239796|t=2020. Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China |pdf=|usr=}}
| |
| − | {{tp|p=32294285|t=2020. Liver impairment associated with disease progression in COVID-19 patients |pdf=|usr=}}
| |
| − | {{tp|p=32348618|t=2020. Author response to Letter to the Editor Liver impairment associated with disease progression in COVID-19 patients |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Kidney, urology]]''' |
| | | | |
| | + | *'''[[The morbid survivor]]''' |
| | | | |
| | + | *'''[[Risk and special populations]]''' |
| | | | |
| | | | |
| | | | |
| | + | *'''[[Case reports]]''' |
| | | | |
| | | | |
| Zeile 197: |
Zeile 96: |
| | | | |
| | | | |
| − |
| |
| − | *'''[[Kidney, urology]]'''
| |
| − | {{tp|p=32249664|t=2020. Focus on the Crosstalk Between COVID-19 and Urogenital Systems |pdf=|usr=}}
| |
| − | {{tp|p=32365180|t=ä. Potential influence of COVID-19/ACE2 on the female reproductive system |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | *'''[[Risk and special populations]]'''
| |
| − | {{tp|p=32369097|t=ä. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32380044|t=ä. Obesity could shift severe COVID-19 disease to younger ages |pdf=|usr=}}
| |
| − | {{tp|p=32376099|t=ä. Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32324209|t=ä. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32242890|t=2020. Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers |pdf=|usr=}}
| |
| − | {{tp|p=32215598|t=ä. Neonatal Early-Onset Infection With SARS-CoV-2 in 33 Neonates Born to Mothers With COVID-19 in Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32171074|t=2020. Comorbidities and multi-organ injuries in the treatment of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32251625|t=2020. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?|pdf=|usr=}}
| |
| − | {{tp|p=32251539|t=2020. COVID-19 and liver disease |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32329563|t=2020. Coronavirus disease 2019 and prevalence of chronic liver disease: A meta-analysis |pdf=|usr=}}
| |
| − | {{tp|p=32243068|t=2020. Breastfeeding and coronavirus disease-2019: Ad interim indications of the Italian Society of Neonatology endorsed by the Union of European Neonatal & Perinatal Societies |pdf=|usr=}}
| |
| − | {{tp|p=32377709|t=2020. Obesity - a risk factor for increased COVID-19 prevalence, severity and lethality |pdf=|usr=}}
| |
| − | {{tp|p=32320556|t=ä. Late-Onset Neonatal Sepsis in a Patient with Covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32356627|t=ä. Renin?Angiotensin?Aldosterone System Blockers and the Risk of Covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32356625|t=ä. Inhibitors of the Renin?Angiotensin?Aldosterone System and Covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32356628|t=ä. Renin?Angiotensin?Aldosterone System Inhibitors and Risk of Covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32347572|t=2020. Outcome of Parkinson s Disease Patients Affected by COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32242182|t=2020. A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019) |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | *'''[[The morbid survivor]]'''
| |
| − | *'''[[Case reports]]'''
| |
| − | {{tp|p=32343395|t=2020. Typically Atypical: COVID-19 Presenting as a Fall in an Older Adult |pdf=|usr=}}
| |
| − | {{tp|p=32227488|t=2020. Diagnosis and treatment of an acute severe pneumonia patient with COVID-19: Case report |pdf=|usr=}}
| |
| − | {{tp|p=32190904|t=2020. Alert for non-respiratory symptoms of Coronavirus Disease 2019 (COVID-19) patients in epidemic period: A case report of familial cluster with three asymptomatic COVID-19 patients |pdf=|usr=}}
| |
| − | {{tp|p=32237278|t=ä. Isolation and rapid sharing of the 2019 novel coronavirus (SARS?CoV?2) from the first patient diagnosed with COVID?19 in Australia |pdf=|usr=}}
| |
| − | {{tp|p=32320564|t=2020. First Case of Covid-19 in the United States |pdf=|usr=}}
| |
| | | | |
| | *'''[[Case series]]''' | | *'''[[Case series]]''' |
| − | {{tp|p=32367888|t=2020. COVID-19 Dynamic Computed Tomography (CT) Performance and Observation of Some Laboratory Indicators |pdf=|usr=}}
| |
| − | {{tp|p=32203977|t=2020. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy |pdf=|usr=}}
| |
| − | {{tp|p=32356945|t=ä. Children with Covid-19 in Pediatric Emergency Departments in Italy |pdf=|usr=}}
| |
| − | {{tp|p=32327757|t=2020. Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| | *'''[[Registries]]''' | | *'''[[Registries]]''' |
| − | {{tp|p=32377641|t=ä. Initial data from the COVID-19 Global Rheumatology Alliance provider registries |pdf=|usr=}}
| |
| − | {{tp|p=32377642|t=ä. Initial data from the COVID-19 Global Rheumatology Alliance provider registries ? Authors reply |pdf=|usr=}}
| |
| − |
| |
| − | ----
| |
| | | | |
| | | | |
| | *'''[[Trials]]''' | | *'''[[Trials]]''' |
| − | {{tp|p=32379296|t=2020. Inclusion of Children in Clinical Trials of Treatments for Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32341581|t=2020. Antibody testing will enhance the power and accuracy of COVID-19-prevention trials |pdf=|usr=}}
| |
| − | {{tp|p=32179860|t=2020. Don t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees |pdf=|usr=}}
| |
| | | | |
| | *'''[[Candidate Compounds Covid19]]''' | | *'''[[Candidate Compounds Covid19]]''' |
| − | {{tp|p=32376627|t=2020. Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity |pdf=|usr=}}
| |
| − | {{tp|p=32359402|t=2020. Considering BCG vaccination to reduce the impact of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32380023|t=ä. Immunomodulation in COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32367857|t=2020. Safety of an immunomodulator Mycobacterium w in COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32367847|t=2020. Nasopharyngeal wash in preventing and treating upper respiratory tract infections: Could it prevent COVID-19?|pdf=|usr=}}
| |
| − | {{tp|p=32371362|t=2020. Mesenchymal stem cell (MSc) secretome: A possible therapeutic strategy for intensive-care COVID-19 patients |pdf=|usr=}}
| |
| − | {{tp|p=32366816|t=2020. An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development |pdf=|usr=}}
| |
| − | {{tp|p=32376359|t=ä. Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32219429|t=2020. Convalescent Plasma to Treat COVID-19: Possibilities and Challenges |pdf=|usr=}}
| |
| − | {{tp|p=32352484|t=2020. Testing an Old Therapy Against a New Disease: Convalescent Plasma for COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32208486|t=2020. Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics |pdf=|usr=}}
| |
| − | {{tp|p=32297900|t=2020. Finding Effective Treatments for COVID-19: Scientific Integrity and Public Confidence in a Time of Crisis |pdf=|usr=}}
| |
| − | {{tp|p=32282022|t=2020. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review |pdf=|usr=}}
| |
| − | {{tp|p=32347894|t=2020. The Risks of Prescribing Hydroxychloroquine for Treatment of COVID-19-First, Do No Harm |pdf=|usr=}}
| |
| − | {{tp|p=32243778|t=2020. Ensuring global access to COVID-19 vaccines |pdf=|usr=}}
| |
| − | {{tp|p=32247324|t=2020. Global coalition to accelerate COVID-19 clinical research in resource-limited settings |pdf=|usr=}}
| |
| − | {{tp|p=32251638|t=2020. Baricitinib for COVID-19: a suitable treatment?|pdf=|usr=}}
| |
| − | {{tp|p=32251639|t=2020. Baricitinib for COVID-19: a suitable treatment? - Authors reply |pdf=|usr=}}
| |
| − | {{ttp|p=32240961|t=2020. Routine childhood immunization may protect against COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32372435|t=2020. Drug repurposing in the era of COVID-19: a call for leadership and government investment |pdf=|usr=}}
| |
| − | {{tp|p=32266987|t=2020. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32324177|t=2020. Some drugs for COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32162456|t=ä. Rapid Identification of Potential Inhibitors of SARS?CoV?2 Main Protease by Deep Docking of 1 3?Billion Compounds |pdf=|usr=}}
| |
| − | {{tp|p=32379955|t=ä. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32375002|t=ä. Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery |pdf=|usr=}}
| |
| − | {{ttp|p=32378459|t=2020. Application of nanomaterials in treatment, anti-infection and detection of coronaviruses |pdf=|usr=}}
| |
| − | {{ttp|p=32363750|t=2020. A Chemographic Audit of anti-Coronavirus Structure-Activity Information from Public Databases (ChEMBL) |pdf=|usr=}}
| |
| − | {{tp|p=32369286|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19 Reply |pdf=|usr=}}
| |
| − | {{tp|p=32227757|t=2020. Developing Covid-19 Vaccines at Pandemic Speed |pdf=|usr=}}
| |
| − | {{tp|p=32289216|t=2020. Drug Evaluation during the Covid-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32332765|t=2020. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig |pdf=|usr=}}
| |
| − | {{tp|p=32273604|t=2020. Lopinavir-ritonavir in severe COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32273591|t=2020. The COVID-19 vaccine development landscape |pdf=|usr=}}
| |
| − | {{tp|p=32269311|t=2020. Coordinating the COVID-19 pipeline |pdf=|usr=}}
| |
| − | {{tp|p=32127666|t=2020. Therapeutic options for the 2019 novel coronavirus (2019-nCoV) |pdf=|usr=}}
| |
| − | {{tp|p=32376938|t=2020. China is promoting coronavirus treatments based on unproven traditional medicines |pdf=|usr=}}
| |
| − | {{tp|p=32272481|t=2020. Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors |pdf=|usr=}}
| |
| − | {{tp|p=32350436|t=2020. Hopes rise for coronavirus drug remdesivir |pdf=|usr=}}
| |
| − | {{tp|p=32355243|t=2020. Scores of coronavirus vaccines are in competition - how will scientists choose the best?|pdf=|usr=}}
| |
| − | {{tp|p=32353859|t=2020. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing |pdf=|usr=}}
| |
| | | | |
| | | | |
| | + | *'''[[Other routes of infection]]''' |
| | | | |
| | | | |
| − | *'''[[Other routes of infection]]''' | + | *'''[[Biophysics of aerosols]]''' |
| − | {{tp|p=32367576|t=2020. Saliva is a non-negligible factor in the spread of COVID-19 |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| − |
| |
| − | *'''[[Biophysics of aerosols]]'''
| |
| − | {{tp|p=32215590|t=2020. Turbulent Gas Clouds and Respiratory Pathogen Emissions: Potential Implications for Reducing Transmission of COVID-19 |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Passive protective equipment]]''' | | *'''[[Passive protective equipment]]''' |
| − | {{tp|p=32320083|t=2020. Decontamination of face masks with steam for mask reuse in fighting the pandemic COVID-19: experimental supports |pdf=|usr=}}
| |
| − |
| |
| − | *'''[[Running your hospital]]'''
| |
| − | {{tp|p=32377176|t=2020. Pancreatic Cancer During COVID-19 Pandemic: Treat or Not to Treat?|pdf=|usr=}}
| |
| − | {{tp|p=32376104|t=ä. Public Health Crises and the Human Subjects of Biomedical Research: A Focus on COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32232420|t=2020. Medical Student Education in the Time of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32364597|t=2020. Ophthalmology After Coronavirus Disease 2019 (COVID-19): Transition Back to Patient Care |pdf=|usr=}}
| |
| − | {{tp|p=32232422|t=2020. Humans, Viruses, and the Eye-An Early Report From the COVID-19 Front Line |pdf=|usr=}}
| |
| − | {{tp|p=32232426|t=2020. Surgical Considerations for Tracheostomy During the COVID-19 Pandemic: Lessons Learned From the Severe Acute Respiratory Syndrome Outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32293940|t=2020. Impact of the COVID-19 Epidemic on a Pan-Asian Academic Oncology Clinical Trial |pdf=|usr=}}
| |
| − | {{tp|p=32250659|t=2020. COVID-19 and Cancer: Lessons From a Pooled Meta-Analysis |pdf=|usr=}}
| |
| − | {{tp|p=32330078|t=2020. Dental Care and Oral Health under the Clouds of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32375197|t=2020. COVID-19: ophthalmologische Aspekte der globalen SARS-CoV-2-Pandemie |pdf=|usr=}}
| |
| − | {{tp|p=32213335|t=2020. COVID-19 and medical education |pdf=|usr=}}
| |
| − | {{tp|p=32368799|t=2020. Utility of Tracheostomy in Patients With COVID-19 and Other Special Considerations |pdf=|usr=}}
| |
| − | {{tp|p=32378325|t=2020. Preliminary Analysis of the Impact of COVID-19 Outbreak on Italian Liver Transplant Programs |pdf=|usr=}}
| |
| − | {{tp|p=32369251|t=2020. Changes in liver transplant center practice in response to COVID-19: Unmasking dramatic center-level variability |pdf=|usr=}}
| |
| − | {{tp|p=32246576|t=2020. Liver transplantation in an ICU dominated by COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32356900|t=2020. Consensus statement: Safe Airway Society principles of airway management and tracheal intubation specific to the COVID-19 adult patient group |pdf=|usr=}}
| |
| − | {{tp|p=32303722|t=2020. Science in the time of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32371961|t=2020. Coronavirus in charts: are virtual conferences here to stay?|pdf=|usr=}}
| |
| − | {{tp|p=32313158|t=2020. How COVID-19 lockdowns could lead to a kinder research culture |pdf=|usr=}}
| |
| − | {{tp|p=32210386|t=2020. Care for laboratory animals during COVID-19 crisis |pdf=|usr=}}
| |
| − | {{tp|p=32127713|t=2020. Extended US travel ban harms global science |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| | + | *'''[[Running your hospital]]''' |
| | | | |
| | | | |
| | *'''[[Mental aspects of health professionals]]''' | | *'''[[Mental aspects of health professionals]]''' |
| − | {{tp|p=32314806|t=2020. Psychological stress of medical staffs during outbreak of COVID-19 and adjustment strategy |pdf=|usr=}}
| |
| | | | |
| | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' | | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' |
| − | {{tp|p=32297903|t=2020. Meeting the Care Needs of Older Adults Isolated at Home During the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32275292|t=2020. The Mental Health Consequences of COVID-19 and Physical Distancing: The Need for Prevention and Early Intervention |pdf=|usr=}}
| |
| − | {{tp|p=32286618|t=2020. Coronavirus Disease 2019 (COVID-19) and Mental Health for Children and Adolescents |pdf=|usr=}}
| |
| − | {{tp|p=32242888|t=2020. Addressing the COVID-19 Pandemic in Populations With Serious Mental Illness |pdf=|usr=}}
| |
| − | {{tp|p=32243784|t=2020. Protecting the psychological health of children through effective communication about COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32302076|t=2020. The Untold Toll - The Pandemic s Effects on Patients without Covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32300212|t=2020. How is biomedical research funding faring during the COVID-19 lockdown?|pdf=|usr=}}
| |
| − | {{tp|p=32269356|t=2020. Science in the time of COVID-19 |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| Zeile 359: |
Zeile 131: |
| | | | |
| | *'''[[Avoiding clinical medicine in other diseases]]''' | | *'''[[Avoiding clinical medicine in other diseases]]''' |
| − | {{tp|p=32359403|t=ä. Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands |pdf=|usr=}}
| + | |
| − | {{tp|p=32343497|t=ä. Reduced Rate of Hospital Admissions for ACS during Covid-19 Outbreak in Northern Italy |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | *'''[[Occupational medicine, workplace security and status hygienicus]]''' | | *'''[[Occupational medicine, workplace security and status hygienicus]]''' |
| | + | |
| | + | |
| | *'''[[Economic aspects of the status hygienicus]]''' | | *'''[[Economic aspects of the status hygienicus]]''' |
| − | {{tp|p=32377508|t=ä. Review on government action plans to reduce energy consumption in buildings amid COVID-19 pandemic outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32273610|t=2020. If the world fails to protect the economy, COVID-19 will damage health not just now but also in the future |pdf=|usr=}}
| |
| − | {{tp|p=32269308|t=2020. COVID-19 brings drug development to a halt |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 375: |
Zeile 145: |
| | | | |
| | *'''[[Host, vector, one health, atmospheric aspects]]''' | | *'''[[Host, vector, one health, atmospheric aspects]]''' |
| − | {{tp|p=32220068|t=ä. Might the many positive COVID19 subjects in Italy have been caused by resident bat?derived zoonotic ??coronaviruses instead of the Wuhan (China) outbreak?|pdf=|usr=}}
| |
| − | {{tp|p=32374472|t=2020. Comments on "Cross-species transmission of the newly identified coronavirus 2019-nCoV" |pdf=|usr=}}
| |
| − | {{tp|p=32346874|t=2020. SARS-CoV-2 and the Hidden Carriers - Sewage, Feline, and Blood Transfusion |pdf=|usr=}}
| |
| − | {{tp|p=32338486|t=2020. Air pollution and SARS-CoV-2 in the Po Valley: possible environmental persistence?|pdf=|usr=}}
| |
| − | {{tp|p=32377007|t=2020. Species distribution models are inappropriate for COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32380510|t=2020. Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins |pdf=|usr=}}
| |
| − | {{tp|p=32218527|t=2020. Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins |pdf=|usr=}}
| |
| − | {{tp|p=32127703|t=2020. Mystery deepens over animal source of coronavirus |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| | | | |
| | *'''[[Origin of Covid19]]''' | | *'''[[Origin of Covid19]]''' |
| | + | |
| | *'''[[Epidemiology]]''' | | *'''[[Epidemiology]]''' |
| − | {{tp|p=32359457|t=2020. Prisons are ?in no way equipped? to deal with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32380045|t=ä. The COVID-19 response for vulnerable people in places affected by conflict and humanitarian crises |pdf=|usr=}}
| |
| − | {{tp|p=32167525|t=2020. From Containment to Mitigation of COVID-19 in the US |pdf=|usr=}}
| |
| − | {{tp|p=32186661|t=2020. Presidential Powers and Response to COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32091533|t=2020. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention |pdf=|usr=}}
| |
| − | {{tp|p=32259189|t=2020. The Challenge of Preventing COVID-19 Spread in Correctional Facilities |pdf=|usr=}}
| |
| − | {{tp|p=32343355|t=2020. COVID-19 in Prisons and Jails in the United States |pdf=|usr=}}
| |
| − | {{tp|p=32259190|t=2020. What Other Countries Can Learn From Italy During the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32356871|t=2020. Contact Tracing, Testing, and Control of COVID-19-Learning From Taiwan |pdf=|usr=}}
| |
| − | {{tp|p=32197103|t=2020. COVID-19: towards controlling of a pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32356573|t=2020. COVID-19: implementing sustainable low cost physical distancing and enhanced hygiene |pdf=|usr=}}
| |
| − | {{tp|p=32333451|t=2020. COVID-19 and Underinvestment in the Health of the US Population |pdf=|usr=}}
| |
| − | {{tp|p=32369276|t=ä. Adaptations and Lessons in the Province of Bergamo |pdf=|usr=}}
| |
| − | {{tp|p=32333418|t=2020. COVID-19 and Underinvestment in the Public Health Infrastructure of the United States |pdf=|usr=}}
| |
| − | {{tp|p=32374952|t=2020. Racial Health Disparities and Covid-19 - Caution and Context |pdf=|usr=}}
| |
| − | {{tp|p=32220207|t=2020. Undocumented U S Immigrants and Covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32240582|t=2020. Flattening the Curve for Incarcerated Populations - Covid-19 in Jails and Prisons |pdf=|usr=}}
| |
| − | {{tp|p=32227759|t=2020. Feeding Low-Income Children during the Covid-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32377018|t=2020. Applying principles of behaviour change to reduce SARS-CoV-2 transmission |pdf=|usr=}}
| |
| − | {{tp|p=32355299|t=2020. Using social and behavioural science to support COVID-19 pandemic response |pdf=|usr=}}
| |
| − | {{tp|p=32246105|t=2020. COVID-19 in Africa |pdf=|usr=}}
| |
| − | {{tp|p=32269357|t=2020. COVID-19 in humanitarian settings and lessons learned from past epidemics |pdf=|usr=}}
| |
| − | {{tp|p=32161414|t=2020. Nigeria responds to COVID-19; first case detected in sub-Saharan Africa |pdf=|usr=}}
| |
| − | {{tp|p=32365354|t=2020. Effect of non-pharmaceutical interventions to contain COVID-19 in China |pdf=|usr=}}
| |
| − | {{tp|p=32332908|t=2020. Distancing is impossible : refugee camps race to avert coronavirus catastrophe |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 420: |
Zeile 155: |
| | | | |
| | *'''[[Remission, recurrence and persistence]]''' | | *'''[[Remission, recurrence and persistence]]''' |
| − | {{tp|p=32296168|t=2020. Temporal dynamics in viral shedding and transmissibility of COVID-19 |pdf=|usr=}}
| + | |
| | + | |
| | | | |
| | *'''[[Failure of executive measures]]''' | | *'''[[Failure of executive measures]]''' |
| | ---- | | ---- |
| | *'''[[Failure of politics and public health guidance]]''' | | *'''[[Failure of politics and public health guidance]]''' |
| − | {{tp|p=32352911|t=2020. COVID-19 reveals weak health systems by design: Why we must re-make global health in this historic moment |pdf=|usr=}}
| + | |
| − | {{tp|p=32273583|t=2020. When COVID-19 meets centralized, personalized power |pdf=|usr=}}
| + | |
| | | | |
| | *'''[[Political abuse of Covid19]]''' | | *'''[[Political abuse of Covid19]]''' |
| − | {{tp|p=32371962|t=2020. Going viral: how to boost the spread of coronavirus science on social media |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| | *'''[[Lost people]]''' | | *'''[[Lost people]]''' |
| − | {{tp|p=32317499|t=2020. A tribute to frontline corona warriors--Doctors who sacrificed their life while saving patients during the ongoing COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32238428|t=2020. Dr Li Wenliang and the Time of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32303602|t=2020. Letter to the Editor: Who was the first doctor to report the Covid-19 outbreak in Wuhan, China?|pdf=|usr=}}
| |
| − | {{tp|p=32310289|t=2020. Health Care Heroes of the COVID-19 Pandemic |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | | | |
| | *'''[[Lost civilization]]''' | | *'''[[Lost civilization]]''' |
| − | {{tp|p=32374357|t=2020. The Ethics of COVID-19 Immunity-Based Licenses ("Immunity Passports") |pdf=|usr=}}
| |
| − | {{tp|p=32380041|t=2020. COVID-19 immunity passports and vaccination certificates: scientific, equitable, and legal challenges |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | | | |
| | ---- | | ---- |
| Zeile 451: |
Zeile 175: |
| | | | |
| | *'''[[History of covid19 exploration]]''' | | *'''[[History of covid19 exploration]]''' |
| − | {{tp|p=32343423|t=2020. A Novel Plan to Deal with SARS-CoV-2 and COVID-19 Disease |pdf=|usr=}}
| + | *'''[[misc.]]''' |
| − | {{tp|p=32211809|t=2020. An Acute Respiratory Infection Runs Into the Most Common Noncommunicable Epidemic-COVID-19 and Cardiovascular Diseases |pdf=|usr=}}
| + | |
| − | {{tp|p=32376535|t=2020. SARS-CoV-2|pdf=|usr=}}
| + | |
| − | {{tp|p=32078595|t=2020. SARS-CoV-2: a novel deadly virus in a globalised world |pdf=|usr=}}
| + | |
| − | {{tp|p=32132688|t=2020. Behind the scenes in the biosafety office |pdf=|usr=}}
| + | |
| − | {{tp|p=31992886|t=2020. This scientist hopes to test coronavirus drugs on animals in locked-down Wuhan |pdf=|usr=}}
| + | |
| − | {{tp|p=32265538|t=2020. The pandemic in pictures: how coronavirus is changing the world |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | + | *'''[[Research tools]]''' |
| | | | |
| | | | |
| − | *'''[[misc.]]'''
| |
| − | {{tp|p=32377057|t=ä. Emerging technologies to combat COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32323591|t=2020. Immunomodulators and immunosuppressants in the era of SARS-CoV-2 - could laboratory tests be the missing link?|pdf=|usr=}}
| |
| − | {{tp|p=32255383|t=2020. Biological treatment use amid the COVID-19 era, a close look at the unresolved perplexity |pdf=|usr=}}
| |
| − | {{tp|p=32301508|t=2020. Assessment of the quality of systematic reviews on COVID-19: A comparative study of previous coronavirus outbreaks |pdf=|usr=}}
| |
| − | {{tp|p=32281667|t=2020. Coronavirus disease 2019: new things to know!|pdf=|usr=}}
| |
| − | {{tp|p=32176775|t=2020. Editorial Concern-Possible Reporting of the Same Patients With COVID-19 in Different Reports |pdf=|usr=}}
| |
| − | {{tp|p=30761819|t=2019. Efficacy of gummy lozenges containing Erysimum as ancillary treatment in children with sore throat |pdf=|usr=}}
| |
| − | {{tp|p=32020116|t=2020. China coronavirus: labs worldwide scramble to analyse live samples |pdf=|usr=}}
| |
| | | | |
| | | | |
| | + | {{tp|p=27490990|t=2017. AVCpred: an integrated web server for prediction and design of antiviral compounds |pdf=|usr=}} |
| | + | {{tp|p=25040500|t=2014. Engineering large viral DNA genomes using the CRISPR?Cas9 system |pdf=|usr=}} |
| | | | |
| − | *'''[[Research tools]]'''
| |
| − | {{tp|p=32339250|t=2020. A potential ex vivo infection model of human induced pluripotent stem cell-3D organoids beyond coronavirus disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32275081|t=2020. Evaluate severe acute respiratory syndrome coronavirus 2 infectivity by pseudoviral particles |pdf=|usr=}}
| |
| − | {{tp|p=32365353|t=2020. Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform |pdf=|usr=}}
| |
| | | | |
| | *'''[[PrePrint scene]]''' | | *'''[[PrePrint scene]]''' |
| | + | |
| | + | |
| | *'''[[from the ads]]''' | | *'''[[from the ads]]''' |
| | + | |
| | *'''[[Current state of coviki.org]]''' | | *'''[[Current state of coviki.org]]''' |
| | *'''[[on-topic personal thoughts]]''' | | *'''[[on-topic personal thoughts]]''' |
| − | {{tp|p=32374952|t=2020. Racial Health Disparities and Covid-19 - Caution and Context |pdf=|usr=}}
| |
